We could not detect a difference between a single l-g dose of ceftriaxone and multidose cefazolin for infection prophylaxis in patients undergoing a vaginal hysterectomy. However, the total acquisition, preparation, and administration costs were greater for the ceftriaxone regimen than they were for the cefazolin regimen. Cefazolin should therefore remain the drug of choice for infection prophylaxis in uncomplicated vaginal hysterectomies.
Infectious morbidity following vaginal hysterectomy has been variously reported to occur in from 24 to 52% of patients, and routine use of perioperative prophylactic antibiotics has been shown to reduce this significantly to between 6 and 10% (3) . Most prophylactic antibiotic regimens have included one preoperative dose followed by two or three postoperative doses. A few studies have shown that the preoperative dose is the critical one and that it may not be necessary to continue prophylactic antibiotics postoperatively (6, 8) . Besides cost-saving considerations, lower levels of antibiotics may result in less of an alteration in the cervicovaginal microbial flora and a lower level of selection of resistant organisms.
Ceftriaxone is a broad-spectrum cephalosporin with a prolonged half-life in serum of approximately 8 h. Its spectrum includes most gram-positive cocci, except enterococci, and most gram-negative rods, except Pseudomonas species and members of the family Bacteroidaceae (MIC, usually 2-16 ,ug/ml). Because both pharmacologic and clinical studies confirm that ceftriaxone is efficacious in treating susceptible bacterial infections with once-daily dosing, we undertook a study of the efficacies, side effects, effects on vaginal bacterial colonization, and comparative costs of a single 1-g preoperative dose of ceftriaxone versus those of a 1-g dose of cefazolin preoperatively and three doses at 8- compared with 11 events in 9 of 65 ceftriaxone-treated patients, 2 of which occurred after discharge. This gave a total patient infection rate of 13.8% (P = 0.197 by the Fisher exact test). Operative site-related infection rates and the incidence of febrile morbidity alone occurred in 4 of 73 cefazolin-treated patients and in 7 of the 65 ceftriaxonetreated patients (P = 0.203 by the Fisher exact test). In the cefazolin group there were four patients with febrile morbidity only and no patients with localized infection. In the ceftriaxone group, five patients developed febrile morbidity only and two acquired a local infection (one patient had a vaginal cuff abscess and one patient had a wound infection).
Symptomatic urinary tract infections occurred more frequently in the ceftriaxone group. There were four lower urinary tract infections in ceftriaxone-treated patients, three of which were enterococcal and one of which was a ceftriaxone-susceptible strain of Escherichia coli. Two cefazolintreated patients developed cystitis; one case was caused by an Enterobacter species that was resistant to cefazolin, and the other was caused by an enterococcus. Asymptomatic urinary tract colonization occurred in six cefazolin-treated patients (Escherichia coli [n = 1], Proteus mirabilis [n = 1], Acinetobacter calcoaceticus [n = 1], and enterococci [n = 3]). Likewise, six ceftriaxone-treated patients were colonized, and interestingly, all patients were colonized with enterococci.
Given the low incidence of infection and the number of patients enrolled in the study, the power of the study to detect a 50% difference was less than 50%. Therefore, we could not conclude that there were no differences in the efficacies of the two prophylactic regimens.
Clinical side effects of the antibiotics were rare. Phlebitis occurred in one cefazolin-treated patient, and three patients Cervicovaginal microflora shifts. Pre-and postoperative cervicovaginal culture rates were as follows: for predominant flora (Vancouver General Hospital), samples from 46 of 47 patients in the cefazolin group were obtained for culture preoperatively, and samples from 46 patients were obtained for culture postoperatively. Of the 42 patients in the ceftriaxone group, samples were obtained from 40 of them for culturing preoperatively and from 37 of them for culturing postoperatively. For any and all growth (Winnipeg Health Sciences Centre), samples from 25 and 24 of 26 cefazolintreated patients were obtained for culture pre-and postoperatively, respectively, and samples from 22 and 20 of the 23 patients who received ceftriaxone were obtained for culture pre-and postoperatively, respectively.
Qualitative differences were noted between the pre-and postoperative vaginal vault swabs from both groups combined (Table 3 ). There was a general decrease in the number of anaerobic isolates obtained postoperatively from patients from the Vancouver center but not in those from the Winnipeg Center. Since the prevalence of these strains was not different preoperatively, this probably reflects a decrease in the counts below the 104/ml detection limit at the Vancouver center. Among the anaerobes, there was a sharp drop in the number of nonsporulating, gram-positive rods, which accounted for the majority of anaerobic strains isolated preoperatively, and an increase in the number of isolates of the families Bacteroidaceae and Peptococcaceae. Preoperatively, anaerobic nonsporulating, gram-negative rods were isolated from 89 of 133 patients from whom samples were obtained for culture, but these isolates were obtained from only 32 of 127 patients 3 to 4 days after surgery (chi-square, 45.4; P < 0.0001).
The aerobic cervicovaginal flora also underwent changes, particularly the streptococci. The most striking alteration was the increase in the frequency of isolation of enterococci. Enterococci were isolated from 17 of 133 (12.8%) patients preoperatively, versus 44 of 127 (34.6%) patients postoperatively (chi-square, 17.3; P < 0.001). This has been observed consistently in patients who receive preoperative cephalosporin prophylaxis and is not an uncommon cause of postoperative urinary tract infections in obstetric and gynecologic patients. In this study, enterococcal urinary tract infections or colonizations occurred in 13 patients, all of whom had postoperative enterococcal vaginal colonization. In contrast, 2 of 5 patients had urinary tract infections or colonizations with organisms other than enterococci and 29 of 109 patients had no urinary tract infections or colonizations. The members of other strains of streptococci, including groups A and B, nonenterococcal group D, and viridans group, were reduced postoperatively.
In contrast to the distribution shifts in the aforementioned organisms, there was no detectable difference preoperatively versus postoperatively in either the genus composition or the number of patients with facultative gram-negative rods or staphylococci. A similar observation was made for Gardnerella vaginalis and Candida species.
The selection of cervicovaginal organisms that were resistant to the drug used for prophylaxis was not common, with the exception of enterococci. Among 17 patients with enterococci preoperatively, 11 received cefazolin and 6 received ceftriaxone. Among 44 patients with vaginal enterococci postoperatively, 19 received cefazolin and 25 received ceftriaxone (pre-versus postoperative differences were not significant). Of 46 cefazolin-treated patients, 7 patients har- Of 42 patients from whom samples were obtained for culture preoperatively, none had nonenterococcal ceftriaxone-resistant organisms as part of their predominant microbial flora.
DISCUSSION
We could not detect a significant difference between a single dose of 1 g of ceftriaxone given preoperatively and one pre-and three postoperative doses of 1 g of cefazolin in preventing infectious morbidity following vaginal hysterectomy. However, as mentioned previously, given the number of patients enrolled in this study, the power of the study was low and a beta error may have precluded the detection of a significantly greater efficacy of cefazolin over that of ceftriaxone, given the observed differences in the rates of infection. We did not compare these therapies with single-dose cefazolin therapy. The latter has been shown to be an effective prophylaxis regimen in patients undergoing vaginal hysterectomy compared with one preoperative and two postoperative doses of either cefazolin itself (10) or cephaloridine (6) or a single preoperative dose of cefoxitin or cefotaxime (4) or cefonicid (10) . Thus, it is the least expensive regimen and has been advocated as the prophylactic regimen of choice in patients undergoing vaginal hysterectomy (4, 5) . Despite this evidence, however, single-dose cefazolin has not been approved for prophylaxis of infections in patients undergoing vaginal hysterectomy either in Canada or the United States (Canadian Health Protection Branch and the U.S. Food and Drug Administration, personal communications, 1989). Some evidence exists that with cefotaxime prophylaxis, postoperative bacteriuria is less (0.9%) with seven 1-g 12-h doses than it is with a single preoperative dose (7) .
The shifts observed in cervicovaginal flora agree with those found in previous studies, with some minor differences. For example, we did not observe vaginal Candida overgrowth with ceftriaxone as has been reported previously (1) , nor did we see a significant increase in resistant aerobic and anaerobic flora with ceftriaxone, as have other investigators who have examined resistance in fecal flora (9) . This may partly be explained by our use of a 1-g instead of a 2-g dose or our quantitative detection limit of 2103 resistant organisms per ml.
Neither cefazolin nor ceftriaxone provided particularly good anaerobic coverage. This does not seem to be a requirement for effective prophylaxis in patients undergoing vaginal hysterectomy, even though, if an established infection develops, vaginal anaerobes are often involved (2, 11) . For example, postoperative infection rates are no different when single-dose cefazolin and single-dose cefoxitin, a good antianaerobic agent are used (4) .
We agree with previous suggestions that single-dose antimicrobial prophylaxis is desirable. In patients who have recently received cephalosporins and who may harbor resistant flora, agents such as ceftriaxone or cefotaxime may be useful. Taking into account the pharmacy's acquisition cost for ceftriaxone, it is still not as cost-effective as a four-dose cefazolin regimen, even though less preparation and nursing time is required. Our regimen of four cefazolin doses is less conventional than that reported in most studies, in which one preoperative and two 8-h postoperative doses of cefazolin were used. The latter would make the cost difference between the two regimens even greater. Although caution is advised in using agents for prophylaxis that may be needed to treat actual infections (5) , there is little evidence suggesting that this is associated with postoperative treatment failures in obstetrics and gynecology.
